Cytotoxic activity of P1218-specific CTLs against primary targets
| . | Donor 1 . | Donor 2 . | Donor 3 . | Donor 4 . | Mean ± SD . |
|---|---|---|---|---|---|
| Effector-target ratio, 30:1 | |||||
| HLA A2+ AML blasts | 19.2 | 37.8 | 28.8 | 10 | 24.0 ± 12.0 |
| HLA A2+ CML PBMCs | 11.3 | 14.4 | 16 | 15.2 | 14.2 ± 2.0 |
| HLA A2− normal PBMCs | 0 | 0.2 | 2.2 | 0.2 | 0.7 ± 1.0 |
| HLA A2+fibroblasts | 0 | 3 | 1.9 | 0 | 1.2 ± 1.5 |
| HLA A2+fibroblasts+P1218 | 28.2 | 34.1 | 38.1 | 12.6 | 28.3 ± 11.2 |
| Effector-target ratio, 5:1 | |||||
| HLA A2+ AML blasts | 10 | 21.4 | 24.6 | 8.9 | 16.2 ± 7.9 |
| HLA A2+ CML PBMCs | 6.9 | 5.3 | 3.9 | 1.9 | 4.5 ± 2.1 |
| HLA A2− normal PBMCs | 0 | 0 | 0 | 0 | 0 ± 0 |
| HLA A2+fibroblasts | 0 | 7.2 | 0 | 0 | 1.8 ± 3.6 |
| HLA A2+ fibroblasts+P1218 | 20.1 | 30.8 | 31.5 | 9.2 | 22.9 ± 10.5 |
| Effector-target ratio, 1:1 | |||||
| HLA A2+ AML blasts | 0 | 17 | 13.6 | 0.9 | 7.9 ± 8.7 |
| HLA A2+ CML PBMCs | 0 | 0 | 0 | 0 | 0 ± 0 |
| HLA A2− normal PBMCs | 0 | 0 | 0 | 0 | 0 ± 0 |
| HLA A2+ fibroblasts | 0 | 3.1 | 1.2 | 0 | 1.1 ± 1.5 |
| HLA A2+fibroblasts+P1218 | 14.4 | 23.2 | 31.6 | 9.7 | 19.7 ± 9.7 |
| . | Donor 1 . | Donor 2 . | Donor 3 . | Donor 4 . | Mean ± SD . |
|---|---|---|---|---|---|
| Effector-target ratio, 30:1 | |||||
| HLA A2+ AML blasts | 19.2 | 37.8 | 28.8 | 10 | 24.0 ± 12.0 |
| HLA A2+ CML PBMCs | 11.3 | 14.4 | 16 | 15.2 | 14.2 ± 2.0 |
| HLA A2− normal PBMCs | 0 | 0.2 | 2.2 | 0.2 | 0.7 ± 1.0 |
| HLA A2+fibroblasts | 0 | 3 | 1.9 | 0 | 1.2 ± 1.5 |
| HLA A2+fibroblasts+P1218 | 28.2 | 34.1 | 38.1 | 12.6 | 28.3 ± 11.2 |
| Effector-target ratio, 5:1 | |||||
| HLA A2+ AML blasts | 10 | 21.4 | 24.6 | 8.9 | 16.2 ± 7.9 |
| HLA A2+ CML PBMCs | 6.9 | 5.3 | 3.9 | 1.9 | 4.5 ± 2.1 |
| HLA A2− normal PBMCs | 0 | 0 | 0 | 0 | 0 ± 0 |
| HLA A2+fibroblasts | 0 | 7.2 | 0 | 0 | 1.8 ± 3.6 |
| HLA A2+ fibroblasts+P1218 | 20.1 | 30.8 | 31.5 | 9.2 | 22.9 ± 10.5 |
| Effector-target ratio, 1:1 | |||||
| HLA A2+ AML blasts | 0 | 17 | 13.6 | 0.9 | 7.9 ± 8.7 |
| HLA A2+ CML PBMCs | 0 | 0 | 0 | 0 | 0 ± 0 |
| HLA A2− normal PBMCs | 0 | 0 | 0 | 0 | 0 ± 0 |
| HLA A2+ fibroblasts | 0 | 3.1 | 1.2 | 0 | 1.1 ± 1.5 |
| HLA A2+fibroblasts+P1218 | 14.4 | 23.2 | 31.6 | 9.7 | 19.7 ± 9.7 |
Cytotoxicity was determined in 51Cr release assays against circulating or bone marrow blasts from 4 HLA-A2+ patients with AML, PBMCs from 4 HLA A2+ healthy controls and 4 patients with CML, and primary fibroblasts from 4 HLA-A2+ healthy controls. Fibroblasts were pretreated with IFN-γ to induce expression of HLA class 1 molecules and, in some experiments, were pulsed with 100 μM P1218 peptide for 1 hour before labeling with 51Cr. Results are the means of triplicate wells.